Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
Romain Marignier, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean Wingerchuk, Kazuko Fujihara, Friedemann Paul, Gary R Cutter, Ari J Green, Orhan Aktas, Hans-Peter Hartung, Fred D Lublin, Ian M Williams, Jorn Drappa, Dewei She, Daniel Cimbora, William Rees, Michael Smith, John N Ratchford, Eliezer Katz, Bruce A C Cree, N-MOmentum Study Investigators, Romain Marignier, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean Wingerchuk, Kazuko Fujihara, Friedemann Paul, Gary R Cutter, Ari J Green, Orhan Aktas, Hans-Peter Hartung, Fred D Lublin, Ian M Williams, Jorn Drappa, Dewei She, Daniel Cimbora, William Rees, Michael Smith, John N Ratchford, Eliezer Katz, Bruce A C Cree, N-MOmentum Study Investigators
Abstract
Objective: To assess treatment effects on Expanded Disability Status Scale (EDSS) score worsening and modified Rankin Scale (mRS) scores in the N-MOmentum trial of inebilizumab, a humanized anti-CD19 monoclonal antibody, in participants with neuromyelitis optica spectrum disorder (NMOSD).
Methods: Adults (N = 230) with aquaporin-4 immunoglobulin G-seropositive NMOSD or -seronegative neuromyelitis optica and an EDSS score ≤8 were randomized (3:1) to receive inebilizumab 300 mg or placebo on days 1 and 15. The randomized controlled period (RCP) was 28 weeks or until adjudicated attack, with an option to enter the inebilizumab open-label period. Three-month EDSS-confirmed disability progression (CDP) was assessed using a Cox proportional hazard model. The effect of baseline subgroups on disability was assessed by interaction tests. mRS scores from the RCP were analyzed by the Wilcoxon-Mann-Whitney odds approach.
Results: Compared with placebo, inebilizumab reduced the risk of 3-month CDP (hazard ratio [HR]: 0.375; 95% CI: 0.148-0.952; p = 0.0390). Baseline disability, prestudy attack frequency, and disease duration did not affect the treatment effect observed with inebilizumab (HRs: 0.213-0.503; interaction tests: all p > 0.05, indicating no effect of baseline covariates on outcome). Mean EDSS scores improved with longer-term treatment. Inebilizumab-treated participants were more likely to have a favorable mRS outcome at the end of the RCP (OR: 1.663; 95% CI: 1.195-2.385; p = 0.0023).
Conclusions: Disability outcomes were more favorable with inebilizumab vs placebo in participants with NMOSD.
Classification of evidence: This study provides Class II evidence that for patients with NMOSD, inebilizumab reduces the risk of worsening disability. N-MOmentum is registered at ClinicalTrials.gov: NCT02200770.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures
References
- Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805–815.
- Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 2014;24:83–97.
- Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390–396.
- Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014;176:149–164.
- Jeong IH, Choi JY, Kim SH, et al. . Normal-appearing white matter demyelination in neuromyelitis optica spectrum disorder. Eur J Neurol 2017;24:652–658.
- Ventura RE, Kister I, Chung S, Babb JS, Shepherd TM. Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions. Neurol Neuroimmunol Neuroinflamm 2016;3:e224.
- Jeong IH, Kim HJ, Kim NH, Jeong KS, Park CY. Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder. J Neurol 2016;263:1343–1348.
- Ringelstein M, Harmel J, Zimmermann H, et al. . Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology 2020;94:e407–e418.
- Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 2016;73:1342–1348.
- Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord 2019;33:22–32.
- Pittock SJ, Berthele A, Fujihara K, et al. . Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 2019;381:614–625.
- Yamamura T, Kleiter I, Fujihara K, et al. . Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019;381:2114–2124.
- Bennett JL, O'Connor KC, Bar-Or A, et al. . B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2:e104.
- Hausser-Kinzel S, Weber MS. The role of B cells and antibodies in multiple sclerosis, neuromyelitis optica, and related disorders. Front Immunol 2019;10:201.
- Cree BAC, Bennett JL, Kim HJ, et al. . Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019;394:1352–1363.
- Cree BA, Bennett JL, Sheehan M, et al. . Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler 2016;22:862–872.
- Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485–1489.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
- van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604–607.
- D'Souza M, Yaldizli O, John R, et al. . Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: a proof of concept study. Mult Scler 2017;23:597–603.
- Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107–1114.
- Pittock SJ, Lennon VA, McKeon A, et al. . Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12:554–562.
- Churilov L, Arnup S, Johns H, et al. . An improved method for simple, assumption-free ordinal analysis of the modified Rankin Scale using generalized odds ratios. Int J Stroke 2014;9:999–1005.
- Divine G, Norton HJ, Hunt R, Dienemann J. Statistical grand rounds: a review of analysis and sample size calculation considerations for Wilcoxon tests. Anesth Analg 2013;117:699–710.
- Kitley J, Leite MI, Nakashima I, et al. . Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135:1834–1849.
- Jarius S, Ruprecht K, Wildemann B, et al. . Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
- Palace J, Lin DY, Zeng D, et al. . Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain 2019;142:1310–1323.
- Kim SH, Mealy MA, Levy M, et al. . Racial differences in neuromyelitis optica spectrum disorder. Neurology 2018;91:e2089–e2099.
- Mealy MA, Mossburg SE, Kim SH, et al. . Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord 2019;28:64–68.
- Viela Bio. UPLINZA (Inebilizumab): Prescribing Information [online]. Available at: . Accessed August 04, 2020.
- Costanzi C, Matiello M, Lucchinetti CF, et al. . Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011;77:659–666.
- Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270–1272.
- Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017;264:2003–2009.
- Tahara M, Oeda T, Okada K, et al. . Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020;19:298–306.
- Alexion Pharmaceuticals Inc. SOLIRIS (Eculizumab): Prescribing Information [online]. Available at: . Accessed April 17, 2020.
- Alexion Europe S.A.S. SOLIRIS (Eculizumab): Summary of Product Characteristics [online]. Available at: . Accessed April 17, 2020.
- Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2021;20:60–67.
- Aktas O, Smith M, Rees W, et al. . Elevated serum glial fibrillary acidic protein (sGFAP) is associated with increased risk of neuromyelitis optica spectrum disorder attacks in the N-MOmentum randomised, masked, placebo-controlled clinical trial of inebilizumab. ECTRIMS Online Libr 2019;278649:P1609.
- Oertel FC, Havla J, Roca-Fernandez A, et al. . Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry 2018;89:1259–1265.
- Oertel FC, Kuchling J, Zimmermann H, et al. . Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm 2017;4:e334.
- Ringelstein M, Kleiter I, Ayzenberg I, et al. . Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler 2014;20:617–620.
Source: PubMed